BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $39

Benzinga · 2d ago
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $38 to $39.